Pharmacopeia
Master Compare
Compare candidate-facing canonical Pharmacopeia fields side by side. Isolated AI-draft proposals are never included.
| Field |
AMPICILLIN
Anti-infectives · Anti-infectives · Level 1
|
VANCOMYCIN
Anti-infectives · Anti-infectives · Level 1
|
|---|---|---|
| Mechanism of action | Contains a beta lactam ring structure. Betalactam antibiotics inhibit the growth of sensitive bacteria by inactivating transpeptidase enzymes located in the bacterial cell membrane, inhibiting crosslinkage of peptidoglycans and thus impairing cell wall synthesis |
Inhibits Glycopeptide synthetase prevents peptidoglycan formation in bacterial cell well |
| Absorption | BA 62% |
bioavailabilty Oral: Poor; I.M.: Erratic; Intraperitoneal: ~38% |
| Distribution | penetration into CSF occurs with inflamed meninges only |
Distributes widely in |
| Protein binding | 20% PB |
~50% PB |
| Volume of distribution | — | Vd: 0.4-1 L/kg |
| Metabolism | Some Hepatic Metabolism |
Little or no metabolism |
| Excretion | Mostly unchanged in urine. |
excretion via kidneys unchanged |
| Half-life | — | half life Biphasic half life, prolonged in renal fail. Mean t1/2 4-6hrs |
| Adverse Effects Toxicity | — | Hypersensitivity reactions including anaphylaxis. |
| Antimicrobial Spectrum | Moderate spectrum |
active against most gram positive bacteria (including staphlycocci, streptococci, enterococci, listeria monocytogenes, clostridium sp, and Bacillus sp.), with limited gram negative activity. |
| Class Group | ANTIBIOTIC: |
ANTIBIOTIC: |
| Indications Uses | — | It possesses a broad spectrum of activity against gram positive bacteria including MRSA. |
| Introduction | Betalactam |
Tricyclic glycopeptide antibiotic produced by streptococcus orientalis |
| Legacy Cicm Level | Level 1 |
Level 1 |
| Presentation | — | Store at 2-8 degrees, clear solution. Slowly due to vessel irritation (& risk of red man syndrome). |
| Resistance Mechanism | Bacteria produce beta lactamases, which hydrolyse and inactivate the antibiotic Resistance |
VanA resistance – gene mutation leading to decreased affinity of peptidoglycan precursors for vancomycin. |